Product Description
Mechanisms of Action: DR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Approved
Approved Countries: Brazil | Chile | Ireland | New Zealand | Peru | Taiwan | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: National Institute on Drug Abuse (NIDA)
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Cocaine-Related Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NIDA-09250-7 | P2 |
Completed |
Cocaine-Related Disorders |
1999-08-01 |
|
NIDA-3-0010-5 | P2 |
Withdrawn |
Cocaine-Related Disorders |
None |